BACKGROUND: Although lenalidomide maintenance therapy has demonstrated improved outcomes after autologous hematopoietic stem cell transplantation (auto-HCT) for patients with multiple myeloma (MM), the impact of the duration of this therapy is not clearly known. METHODS: This study retrospectively analyzed all MM patients who were placed on maintenance lenalidomide after auto-HCT between January 2007 and December 2013. Progression-free survival (PFS) and overall survival (OS) were analyzed in multivariate Cox proportional hazards regression models that included the duration of maintenance as a time-dependent covariate. RESULTS: Of the 464 patients identified, 46% initiated therapy early (<4 months after auto-HCT). The median PFS and OS were 38 and 78 months, respectively. Improvements in PFS (hazard ratio [HR], 0.13; 95% confidence interval [CI], 0.04-0.38; P < .001) and OS (HR, 0.09; 95% CI, 0.03-0.26; P < .001) were seen for those on maintenance for >2 years versus those on maintenance for ≤2 years. For those on maintenance for >3 versus those on maintenance for ≤3 years, this trend continued with improvements seen in PFS (HR, 0.02; 95% CI, 0.00-0.44; P = .012) and OS (HR, 0.05; 95% CI, 0.00-0.83; P = .037). The incidence of second primary malignancies (SPMs) in the entire cohort was 3%. No differences were seen in survival between early and late initiators of maintenance lenalidomide. CONCLUSIONS: A longer duration of maintenance therapy was associated with longer survival. The incidence of SPMs was low, and they were not associated with the duration of maintenance. The timing of the initiation of maintenance had no effect on survival. Cancer 2016;122:3831-3837.
BACKGROUND: Although lenalidomide maintenance therapy has demonstrated improved outcomes after autologous hematopoietic stem cell transplantation (auto-HCT) for patients with multiple myeloma (MM), the impact of the duration of this therapy is not clearly known. METHODS: This study retrospectively analyzed all MMpatients who were placed on maintenance lenalidomide after auto-HCT between January 2007 and December 2013. Progression-free survival (PFS) and overall survival (OS) were analyzed in multivariate Cox proportional hazards regression models that included the duration of maintenance as a time-dependent covariate. RESULTS: Of the 464 patients identified, 46% initiated therapy early (<4 months after auto-HCT). The median PFS and OS were 38 and 78 months, respectively. Improvements in PFS (hazard ratio [HR], 0.13; 95% confidence interval [CI], 0.04-0.38; P < .001) and OS (HR, 0.09; 95% CI, 0.03-0.26; P < .001) were seen for those on maintenance for >2 years versus those on maintenance for ≤2 years. For those on maintenance for >3 versus those on maintenance for ≤3 years, this trend continued with improvements seen in PFS (HR, 0.02; 95% CI, 0.00-0.44; P = .012) and OS (HR, 0.05; 95% CI, 0.00-0.83; P = .037). The incidence of second primary malignancies (SPMs) in the entire cohort was 3%. No differences were seen in survival between early and late initiators of maintenance lenalidomide. CONCLUSIONS: A longer duration of maintenance therapy was associated with longer survival. The incidence of SPMs was low, and they were not associated with the duration of maintenance. The timing of the initiation of maintenance had no effect on survival. Cancer 2016;122:3831-3837.
Authors: C Fernández de Larrea; R A Kyle; B G M Durie; H Ludwig; S Usmani; D H Vesole; R Hajek; J F San Miguel; O Sezer; P Sonneveld; S K Kumar; A Mahindra; R Comenzo; A Palumbo; A Mazumber; K C Anderson; P G Richardson; A Z Badros; J Caers; M Cavo; X LeLeu; M A Dimopoulos; C S Chim; R Schots; A Noeul; D Fantl; U-H Mellqvist; O Landgren; A Chanan-Khan; P Moreau; R Fonseca; G Merlini; J J Lahuerta; J Bladé; R Z Orlowski; J J Shah Journal: Leukemia Date: 2012-11-21 Impact factor: 11.528
Authors: Antonio Palumbo; Roman Hajek; Michel Delforge; Martin Kropff; Maria Teresa Petrucci; John Catalano; Heinz Gisslinger; Wiesław Wiktor-Jędrzejczak; Mamia Zodelava; Katja Weisel; Nicola Cascavilla; Genadi Iosava; Michele Cavo; Janusz Kloczko; Joan Bladé; Meral Beksac; Ivan Spicka; Torben Plesner; Joergen Radke; Christian Langer; Dina Ben Yehuda; Alessandro Corso; Lindsay Herbein; Zhinuan Yu; Jay Mei; Christian Jacques; Meletios A Dimopoulos Journal: N Engl J Med Date: 2012-05-10 Impact factor: 91.245
Authors: Philip L McCarthy; Kouros Owzar; Craig C Hofmeister; David D Hurd; Hani Hassoun; Paul G Richardson; Sergio Giralt; Edward A Stadtmauer; Daniel J Weisdorf; Ravi Vij; Jan S Moreb; Natalie Scott Callander; Koen Van Besien; Teresa Gentile; Luis Isola; Richard T Maziarz; Don A Gabriel; Asad Bashey; Heather Landau; Thomas Martin; Muzaffar H Qazilbash; Denise Levitan; Brian McClune; Robert Schlossman; Vera Hars; John Postiglione; Chen Jiang; Elizabeth Bennett; Susan Barry; Linda Bressler; Michael Kelly; Michele Seiler; Cara Rosenbaum; Parameswaran Hari; Marcelo C Pasquini; Mary M Horowitz; Thomas C Shea; Steven M Devine; Kenneth C Anderson; Charles Linker Journal: N Engl J Med Date: 2012-05-10 Impact factor: 91.245
Authors: Rafael Alonso; María-Teresa Cedena; Sandy Wong; Nina Shah; Rafael Ríos-Tamayo; José M Moraleda; Javier López-Jiménez; Cristina García; Natasha Bahri; Antonio Valeri; Ricardo Sánchez; Luis Collado-Yurrita; Thomas Martin; Jeffrey Wolf; Juan-José Lahuerta; Joaquín Martínez-López Journal: Blood Adv Date: 2020-05-26
Authors: Philip L McCarthy; Sarah A Holstein; Maria Teresa Petrucci; Paul G Richardson; Cyrille Hulin; Patrizia Tosi; Sara Bringhen; Pellegrino Musto; Kenneth C Anderson; Denis Caillot; Francesca Gay; Philippe Moreau; Gerald Marit; Sin-Ho Jung; Zhinuan Yu; Benjamin Winograd; Robert D Knight; Antonio Palumbo; Michel Attal Journal: J Clin Oncol Date: 2017-07-25 Impact factor: 44.544
Authors: Dilan A Patel; Ragisha Gopalakrishnan; Brian G Engelhardt; Evonne McArthur; Salyka Sengsayadeth; Katie A Culos; Michael Byrne; Stacey Goodman; Bipin N Savani; Wichai Chinratanalab; Madan Jagasia; Claudio A Mosse; Robert F Cornell; Adetola A Kassim Journal: Bone Marrow Transplant Date: 2020-01-28 Impact factor: 5.483
Authors: Sini Luoma; Pekka Anttila; Marjaana Säily; Tuija Lundan; Jouni Heiskanen; Timo Siitonen; Sakari Kakko; Mervi Putkonen; Hanna Ollikainen; Venla Terävä; Marja Sankelo; Anu Partanen; Kirsi Launonen; Anu Räsänen; Anu Sikiö; Merja Suominen; Piotr Bazia; Kristiina Kananen; Juha Lievonen; Tuomas Selander; Tarja-Terttu Pelliniemi; Sorella Ilveskero; Virva Huotari; Pentti Mäntymaa; Anri Tienhaara; Esa Jantunen; Raija Silvennoinen Journal: Ann Hematol Date: 2019-10-31 Impact factor: 3.673